Cardiovascular risk stratification in overweight or obese patients in primary prevention. Implications for use of statins. Masson, W.; Lobo, M.; Huerin, M.; Molinero, G.; Manente, D.; Pangaro, M.; Vitagliano, L.; and Zylbersztejn, H. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 62(2):83-90, 2, 2015.
abstract   bibtex   
BACKGROUND AND OBJECTIVES: Cardiovascular risk estimation in patients with overweight/obesity is not standardized. Our objectives were to stratify cardiovascular risk using different scores, to analyze use of statins, to report the prevalence of carotid atherosclerotic plaque (CAP), and to determine the optimal cut-off point (OCP) of scores that discriminate between subjects with or without CAP. MATERIAL AND METHODS: Non-diabetic patients with overweight or obesity in primary prevention were enrolled. The Framingham score (FS), the European score (ES), and the score proposed by the new American guidelines (NS) were calculated, and statin indication was evaluated. Prevalence of CAP was determined by ultrasound examination. A ROC analysis was performed. RESULTS: A total of 474 patients (67% with overweight and 33% obese) were enrolled into the study. The FS classified the largest number of subjects as low risk. PAC prevalence was higher in obese as compared to overweight subjects (44.8% vs. 36.1%, P=.04). According to the FS, ES, and NS respectively, 26.7%, 39.1%, and 39.1% of overweight subjects and 28.6%, 39.0%, and 39.0% of obese subjects had an absolute indication for statins. All three scores were shown to acceptably discriminate between subjects with and without CAP (area under the curve>0.7). The OCPs evaluated did not agree with the risk category values. CONCLUSIONS: Risk stratification and use of statins varied in the overweight/obese population depending on the function used. Understanding of the relationship between scores and presence of CAP may optimize risk estimate.
@article{
 title = {Cardiovascular risk stratification in overweight or obese patients in primary prevention. Implications for use of statins.},
 type = {article},
 year = {2015},
 identifiers = {[object Object]},
 keywords = {Adult,Cardiovascular Diseases,Carotid Artery Diseases,Coronary Disease,Cross-Sectional Studies,Dyslipidemias,Female,Humans,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Hypertension,Male,Middle Aged,Obesity,Overweight,Prevalence,Primary Prevention,ROC Curve,Risk Assessment,Severity of Illness Index,Smoking,complications,diagnostic imaging,drug therapy,epidemiology,etiology,genetics,prevention & control,therapeutic use},
 pages = {83-90},
 volume = {62},
 month = {2},
 id = {7c321667-e764-3240-b0a2-2d9a3ec12da2},
 created = {2019-12-05T12:38:08.442Z},
 file_attached = {false},
 profile_id = {3bb26c79-1cd6-3945-ac65-a972949fa8b1},
 group_id = {2f9515a1-f4bb-3e7d-9747-925ba4576996},
 last_modified = {2019-12-05T12:38:08.442Z},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {true},
 hidden = {false},
 source_type = {Journal Article, Multicenter Study},
 language = {eng},
 country = {Spain},
 patent_owner = {NLM},
 private_publication = {false},
 abstract = {BACKGROUND AND OBJECTIVES: Cardiovascular risk estimation in patients with overweight/obesity is not standardized. Our objectives were to stratify cardiovascular risk using different scores, to analyze use of statins, to report the prevalence of carotid atherosclerotic plaque (CAP), and to determine the optimal cut-off point (OCP) of scores that discriminate between subjects with or without CAP. MATERIAL AND METHODS: Non-diabetic patients with overweight or obesity in primary prevention were enrolled. The Framingham score (FS), the European score (ES), and the score proposed by the new American guidelines (NS) were calculated, and statin indication was evaluated. Prevalence of CAP was determined by ultrasound examination. A ROC analysis was performed. RESULTS: A total of 474 patients (67% with overweight and 33% obese) were enrolled into the study. The FS classified the largest number of subjects as low risk. PAC prevalence was higher in obese as compared to overweight subjects (44.8% vs. 36.1%, P=.04). According to the FS, ES, and NS respectively, 26.7%, 39.1%, and 39.1% of overweight subjects and 28.6%, 39.0%, and 39.0% of obese subjects had an absolute indication for statins. All three scores were shown to acceptably discriminate between subjects with and without CAP (area under the curve>0.7). The OCPs evaluated did not agree with the risk category values. CONCLUSIONS: Risk stratification and use of statins varied in the overweight/obese population depending on the function used. Understanding of the relationship between scores and presence of CAP may optimize risk estimate.},
 bibtype = {article},
 author = {Masson, Walter and Lobo, Martin and Huerin, Melina and Molinero, Graciela and Manente, Diego and Pangaro, Mario and Vitagliano, Laura and Zylbersztejn, Horacio},
 journal = {Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion},
 number = {2}
}
Downloads: 0